Industry litigation – Page 9
-
BusinessAsia’s age of regulation
Safety legislation and data sharing in Asia is making progress but highlights a global challenge
-
BusinessUS firm fined for mishandling ammonia
Demakes will pay $130,000 to settle violations and has spent $300,000 upgrading systems
-
-
BusinessMylan settles Epipen overcharging allegations
Company will pay US Department of Justice $465m for avoiding paying rebates to government healthcare systems
-
BusinessAirgas fined for fatal nitrogen leak at US sperm bank
$300,000 penalty for leak caused by over-pressurisation after Airgas failed to update tank safety label
-
BusinessUS court denies Amgen appeal over Pfizer biosimilar
Amgen has lost its bid to compel Pfizer to divulge information about its version of anaemia drug Epogen
-
BusinessCelgene pays $280m to settle off-label marketing lawsuit
Whistleblower case relating to cancer prescriptions
-
BusinessLilly wins chemotherapy patent appeal
Firm also settles with generic manufacturers of erectile dysfunction drug Cialis
-
BusinessMallinckrodt settles US opioid lawsuit
Firm will pay $35m over allegations it failed to report suspicious orders of controlled substances
-
BusinessEU to investigate Merck KGaA’s merger with Sigma–Aldrich
Commission says Merck failed to disclose a crucial research project
-
BusinessSilence Therapeutics and Alnylam in patent dispute
Suit alleges competitors need to license Silence patents relating to their drug cantidates
-
BusinessGM corn growers win US lawsuit against Syngenta
Kansas jury awards over $217m damages to farmers in the first of eight trials
-
BusinessFDA asks Endo to take pain drug off market
Request part of larger strategy to address opioid misuse in the US
-
BusinessUS supreme court limits patent rights
Biotech industry is concerned that ruling will hit small companies
-
BusinessDow will face dioxin suit
US appeals court rules property owners have a valid case over soil contamination
-
BusinessEuropean Commission to investigate excessive drug pricing
Inquiry covers claims that Aspen Pharma’s price rises on five cancer treatments were unjustified
-
BusinessGE accused of exposing workers to toxic chemicals
Canadian union says dangerous compounds were used without proper worker protection
-
BusinessSeattle Genetics cancels Immunomedics deal
Settlement also resolves disputes with shareholders
-
NewsLegal battles stall US biosimilars
Unclear legislation and lack of regulatory guidance means companies are turning to the courts
-
BusinessJ&J fights talc cancer claims
Firm has lost several court cases linking talc to ovarian cancer, but vows to appeal